Abstract |
Multifunctional agents aiming at cholinesterases ( ChEs) and monoamine oxidases (MAOs) are promising therapy for Alzheimer's disease (AD). Herein, a series of novel propargylamine-modified pyrimidinylthiourea derivatives (1-4) were designed and synthesized as dual inhibitors of ChEs and MAOs with other functions against AD. Most of these derivatives inhibited ChEs and MAOs with IC50 values in the micro- or nanomolar ranges. Compound 1c displayed the dual functional profile of targeting the AChE (IC50 = 0.032 ± 0.007 μM) and MAO-B (IC50 = 2.117 ± 0.061 μM), along with the improved blood-brain barrier (BBB) permeability, antioxidant ability, and good copper chelating property in vitro. Animal studies showed that compound 1c·HCl could inhibit the cerebral AChE/ MAO-B activities and alleviate scopolamine-induced cognitive impairment in mice. Combined with good oral bioavailability ( F = 45.55%), these findings demonstrated that compound 1c may be a potent brain permeable multifunctional candidate for the treatment of AD.
|
Authors | Yixiang Xu, Jian Zhang, Huan Wang, Fei Mao, Keting Bao, Wenwen Liu, Jin Zhu, Xiaokang Li, Haiyan Zhang, Jian Li |
Journal | ACS chemical neuroscience
(ACS Chem Neurosci)
Vol. 10
Issue 1
Pg. 482-496
(01 16 2019)
ISSN: 1948-7193 [Electronic] United States |
PMID | 30110536
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Cholinesterase Inhibitors
- Monoamine Oxidase Inhibitors
- Monoamine Oxidase
- Acetylcholinesterase
|
Topics |
- Acetylcholinesterase
(metabolism)
- Alzheimer Disease
(drug therapy, enzymology)
- Animals
- Blood-Brain Barrier
(drug effects, metabolism)
- Cholinesterase Inhibitors
(administration & dosage, chemistry, metabolism)
- Drug Delivery Systems
(methods)
- Drug Design
- Mice
- Mice, Inbred ICR
- Monoamine Oxidase
(metabolism)
- Monoamine Oxidase Inhibitors
(administration & dosage, chemistry, metabolism)
|